Cutting Edge Science

Skip To Main Content

This website is intended exclusively for healthcare professionals residing and/or working in Kuwait.

Campus

Login
Registration

Science
Asthma
Atopic Dermatitis
Bullous Pemphigoid
Chronic Obstructive Pulmonary Disease
Diabetes
Eosinophilic Esophagitis
Immune Thrombocytopenia ITP
Multiple Myeloma
Nasal Polyps
Neurological Disorders
Prurigo Nodularis
Rare Diseases
Transplant
Immunology-Pipeline

Acquired Thrombotic Thrombocytopenic Purpura (ATTP)
Hemophilia

Cardiovascular
Atherothrombosis
Dyslipidemia
Hypertension
Thrombosis

Multiple Sclerosis
Smoldering Neuroinflammation

Vaccines
Influenza
RSV
Mass Gathering

Rhinology
Cutting Edge Science

Patient Support
Atopic Dermatitis
Cardiovascular
Rare Diseases
Transplant

Diabetes
My Dose Coach Inquiry

Vaccines
RSV

Product
Adacel®
Cerezyme®
Myozyme®
Nexviazyme
Xatral®
Xenpozyme®

Aldurazyme®
Expert's Videos
Dosing Calculator

Aubagio®
Aubagio vs Ofatumumab

Beyfortus®
International Recommendation
Conferences
Real World Evidence
Clinical Experience
Nirsevimab Use Guidance Video

Cablivi®
aTTP Sphere Digital Case Library
Cablivi® aTTP Patients Voice

Clexane®
Surgical Patients
Hemodialysis

Dupixent®
Dupixent® COPD
Dupixent Asthma
Nasal Polyps
Dupixent Chronic Spontaneous Urticaria

Fabrazyme®
Quantifying the Effect of Fabrazyme
Canadian Fabry Disease Initiative
Long Term Renal Function

Praluent®
RWE Alirocumab and mace in ascvd patients without prior event

It's Praluent of Course
Of Course
What is PRALUENT®?
Why choose PRALUENT®?
How to use PRALUENT®?

Rezurock®
Safety
Mechanism of Action
Dosing

Impact of cVGHD
Challenges of Disease Progression

Efficacy
Efficacy Data

Sarclisa®
Sarclisa®
IMROZ Results
GMMG-HD7 Results
IKEMA Results
ICARIA-MM Results
Dosing & Administration
Mechanism of Action

Soliqua®
For a Peaceful Ramadan
Post-GLP Podcast: needs of patients on GLP-1 RA with basal insulin
Soliqua Unmet Needs Video
Meet The Expert
Soliqua Easy Start®
Soliqua SoliD®
Soliqua Guidelines®
Soliqua Data Set®
Soliqua Simplicity®
Soliqua Safety®
Soliqua®
Reimbursement
Limitations of Premixed Insulin

Toujeo®
Toujeo for a Peaceful Ramadan
Second generation basal insulin in advancing T2D therapy
Timely insulin initiation to limit disease progression
Meet the Expert
Wall of Evidence
How to Start
Time in Range

Toujeo T1DM
OneCare
Edition Junior
UltraFlexi-1
Type-1 Meta Analysis
Guidelines

Toujeo T2DM
Deliver-G
Guidelines

Toujeo Innovation
Toujeo Upgrade to Win

Always On
How to Start People with Diabetes to Toujeo
Bridging the Glycemic Gap- Timely Transition from OADs to Toujeo
Evolving Basal Insulin Therapy- From 1st Gen to 2nd Gen
The Kidney-Diabetes Connection- Clinical Use of Toujeo in Dual Diagnosis
Toujeo vs Degludec- Clinical Insights from the BRIGHT study for Insulin selection
Toujeo and GLP1s- Optimising Glycemic Control in Uncontrolled T2D
New Findings on Toujeo® for T2D Management Following Dual GIP-GLP-1 RA Therapy

Zympass®
Tolerability
Usage

Tzield®
Efficacy and Safety
Stages of T1D
Who to Screen
How to Screen
Dosing & Administration

Campus

Science
Asthma
Atopic Dermatitis
Bullous Pemphigoid
Chronic Obstructive Pulmonary Disease
Diabetes
Eosinophilic Esophagitis
Immune Thrombocytopenia ITP
Multiple Myeloma
Nasal Polyps
Neurological Disorders
Prurigo Nodularis
Rare Diseases
Transplant
Immunology-Pipeline

Acquired Thrombotic Thrombocytopenic Purpura (ATTP)
Hemophilia

Cardiovascular
Atherothrombosis
Dyslipidemia
Hypertension
Thrombosis

Multiple Sclerosis
Smoldering Neuroinflammation

Vaccines
Influenza
RSV
Mass Gathering

Rhinology
Cutting Edge Science

Patient Support
Atopic Dermatitis
Cardiovascular
Rare Diseases
Transplant

Diabetes
My Dose Coach Inquiry

Vaccines
RSV

Product
Adacel®
Cerezyme®
Myozyme®
Nexviazyme
Xatral®
Xenpozyme®

Aldurazyme®
Expert's Videos
Dosing Calculator

Aubagio®
Aubagio vs Ofatumumab

Beyfortus®
International Recommendation
Conferences
Real World Evidence
Clinical Experience
Nirsevimab Use Guidance Video

Cablivi®
aTTP Sphere Digital Case Library
Cablivi® aTTP Patients Voice

Clexane®
Surgical Patients
Hemodialysis

Dupixent®
Dupixent® COPD
Dupixent Asthma
Nasal Polyps
Dupixent Chronic Spontaneous Urticaria

Fabrazyme®
Quantifying the Effect of Fabrazyme
Canadian Fabry Disease Initiative
Long Term Renal Function

Praluent®
RWE Alirocumab and mace in ascvd patients without prior event

It's Praluent of Course
Of Course
What is PRALUENT®?
Why choose PRALUENT®?
How to use PRALUENT®?

Rezurock®
Safety
Mechanism of Action
Dosing

Impact of cVGHD
Challenges of Disease Progression

Efficacy
Efficacy Data

Sarclisa®
Sarclisa®
IMROZ Results
GMMG-HD7 Results
IKEMA Results
ICARIA-MM Results
Dosing & Administration
Mechanism of Action

Soliqua®
For a Peaceful Ramadan
Post-GLP Podcast: needs of patients on GLP-1 RA with basal insulin
Soliqua Unmet Needs Video
Meet The Expert
Soliqua Easy Start®
Soliqua SoliD®
Soliqua Guidelines®
Soliqua Data Set®
Soliqua Simplicity®
Soliqua Safety®
Soliqua®
Reimbursement
Limitations of Premixed Insulin

Toujeo®
Toujeo for a Peaceful Ramadan
Second generation basal insulin in advancing T2D therapy
Timely insulin initiation to limit disease progression
Meet the Expert
Wall of Evidence
How to Start
Time in Range

Toujeo T1DM
OneCare
Edition Junior
UltraFlexi-1
Type-1 Meta Analysis
Guidelines

Toujeo T2DM
Deliver-G
Guidelines

Toujeo Innovation
Toujeo Upgrade to Win

Always On
How to Start People with Diabetes to Toujeo
Bridging the Glycemic Gap- Timely Transition from OADs to Toujeo
Evolving Basal Insulin Therapy- From 1st Gen to 2nd Gen
The Kidney-Diabetes Connection- Clinical Use of Toujeo in Dual Diagnosis
Toujeo vs Degludec- Clinical Insights from the BRIGHT study for Insulin selection
Toujeo and GLP1s- Optimising Glycemic Control in Uncontrolled T2D
New Findings on Toujeo® for T2D Management Following Dual GIP-GLP-1 RA Therapy

Zympass®
Tolerability
Usage

Tzield®
Efficacy and Safety
Stages of T1D
Who to Screen
How to Screen
Dosing & Administration

Login
Registration

Sort by

Allergic Fungal Rhinosinusitis Disease Burden

Learn more

Dupilumab for Patients with AFRS

Learn more

Campus

Privacy Notice Update

We have updated our Privacy Notice for Healthcare Professionals to improve your experience collaborating with us, maintain high standards of privacy and ultimately strengthen the trust you place in us.

Key improvements include enhanced clarity on why and how Sanofi processes your personal data.

Legal notice Cookie policy Privacy policy Sitemap Change country

© Sanofi 2004- - All rights reserved

MAT-KW-2600155/V1/APR2026

SANOFI, Level 3, One JLT, Jumeirah Lake Towers (JLT), DMCC, PO Box 53899, Dubai, UAE Tel.: +971 4 550 3600 | Fax: +971 4 5521050

For further medical information, please contact: For UAE ✆ 800 MEDICAL Toll-Free Number. For all Gulf countries +971 45 50 38 63 or email: medical-information.gulf@sanofi.com.

To report an adverse event or drug reaction, please contact us on: 24/ 7 Pharmacovigilance reporting number: +971 561747001 e-mail: gulf.pharmacovigilance@sanofi.com